Neoleukin faces 3 stockholder suits over Neurogene merger; issues supplemental disclosures

Neurogene Inc.

Three lawsuits and ten demands received from stockholders challenging the merger and proxy disclosures.
Company denies any legal violations but provides supplemental disclosures to avoid litigation disruption.
Supplemental disclosures amend sections on Transaction Committee composition, valuation DCF, and selected public company analyses.
DCF implied Neurogene equity value of $445M-$560M; selected companies analysis with 20% illiquidity discount used.
Executive officers Sean Smith and Donna Cochener entered post-merger consulting negotiations for transition and CVR matters.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.